Clinical Trial Update: Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Circadin 2 mg in patients with mild-to-moderate Alzheimer's disease who are on acetylcholinesterase inhibitors. The study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Circadin (melatonin)

Snippet

Sponsor: Neurim Pharmaceuticals Ltd. | Conditions: Alzheimer's Disease, Sleep Disorder | Phase 2 | Status: COMPLETED | Results posted: 2018-06-01